Prostate Cancer Treatment Shows Promising Data From This Company
GT Biopharma's GTB-5550 Shows Promise in Treating Prostate Cancer.
GT Biopharma recently announced positive preclinical data highlighting the potential of GTB-5550, its novel TriKE molecule, as a targeted treatment for prostate cancer. The data was presented at the 2023 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 1-5 in San Diego.
In preclinical studies, GTB-5550 eliminated B7H3-expressing prostate cancer cells through redirected lysis. It also showed the ability to directly kill chemoresistant prostate cancer stem cells. These early findings suggest GTB-5550's potential to address major challenges in treating advanced prostate cancer.
Anthony Cataldo, CEO of GT Biopharma, noted:
“We are very encouraged by these early preclinical results and believe they provide strong rationale for further developing GTB-5550 as a targeted therapeutic for prostate cancer, including metastatic castrate-resistant prostate cancer.”
Prostate cancer is the second most common cancer in American men after skin cancer. About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. While localized disease can be effectively treated with surgery or radiation, treatment options are limited for advanced and metastatic prostate cancer.
Immunotherapy is emerging as a promising approach to treat prostate cancer. Bispecific NK cell engagers like GTB-5550 offer a way to selectively eliminate cancer cells by activating and redirecting the body's innate immune cells. Additional preclinical studies and clinical trials will be needed to further evaluate GTB-5550's efficacy and safety.
GT Biopharma is a clinical stage biotechnology company focused on developing novel immuno-oncology products. In addition to GTB-5550, the company has several TriKE product candidates targeting various solid tumor types.
As an investor it's important to stay updated with major news. Get real-time alerts by creating an account here.
Sources:
2. Biospace